How many drugs treat Obesity?

Drug Landscape tracks 10 marketed treatments for Obesity (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/obesity.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Obesity — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Obesity (Metabolic & Endocrinology) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Metabolic & Endocrinology 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Obesity, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Imcivree	SETMELANOTIDE	Rhythm	Melanocortin 4 Receptor Agonist [EPC]	Melanocortin receptor 4	2020-01-01
Fintepla	FENFLURAMINE	UCB	fenfluramine	Alpha-1B adrenergic receptor	2020-01-01
Ozempic	semaglutide	Novo Nordisk	GLP-1 Receptor Agonist [EPC]	GLP-1 receptor	2017-01-01
Belviq	LORCASERIN	Eisai	Serotonin-2c Receptor Agonist	5-hydroxytryptamine receptor 2C	2012-01-01
Wellbutrin	bupropion	GSK (GlaxoSmithKline)	NDRI (Norepinephrine-dopamine reuptake inhibitor)	Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor	1985-12-30
Fenmetrazina	PHENMETRAZINE	Boehringer Ingelheim	phenmetrazine	Sodium-dependent noradrenaline transporter	1982-01-01
Didrex	BENZPHETAMINE	Pfizer	Sympathomimetic Amine Anorectic	Alpha-1A adrenergic receptor	1960-01-01
Tenuate	DIETHYLPROPION	ANI Pharmaceuticals	Sympathomimetic Amine Anorectic	Sodium-dependent dopamine transporter	1959-01-01
Amphetamine Sulfate	AMPHETAMINE SULFATE	Azurity	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	1955-01-01
Amphetamine Sulfate	amfetamine	UCB	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	1955-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 8 drugs in Obesity
UCB · 2 drugs in Obesity
Boehringer Ingelheim · 2 drugs in Obesity
Pfizer · 2 drugs in Obesity
Pfizer Inc. · 2 drugs in Obesity
Columbia University · 1 drug in Obesity
Eisai · 1 drug in Obesity
GSK (GlaxoSmithKline) · 1 drug in Obesity
Institute of Liver and Biliary Sciences, India · 1 drug in Obesity
Khoo Teck Puat Hospital · 1 drug in Obesity
Mclean Hospital · 1 drug in Obesity
Novo Nordisk · 1 drug in Obesity

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Obesity:

Cite this brief

Drug Landscape (2026). Obesity — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/obesity. Accessed 2026-06-09.

Obesity full disease profile — treatment pathway, diagnostics, guidelines
Metabolic & Endocrinology area landing
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing